Document is current
Any future updates will be listed below
-
Authors
Fletcher, Simon http://orcid.org/0000-0001-9018-6176
Jenner, Kathryn http://orcid.org/0000-0002-2704-0606
Pembroke, Luke http://orcid.org/0000-0002-2024-6898
Holland, Michael http://orcid.org/0000-0002-9173-4100
Khair, Kate http://orcid.org/0000-0003-2001-5958
-
Funding
Funding for this research was provided by:
uniQure Biophpharma BV (2-061.003)
- License Information
-
More Information
Article History
Received: 12 November 2021
Accepted: 13 February 2022
First Online: 4 April 2022
Declarations
:
: All participants were sent detailed information sheets informing them of the nature and purposes of the research. Written informed consent was obtained. All participants received a gift voucher as a ‘thank you’ for the time they gave attending interviews. Ethical approval for all elements of the study was granted by the UK Healthcare Research Authority and the South East Scotland Research Ethics Committee (20/SS/0061).
: No applicable.
: S Fletcher. Unrestricted educational grant from Roche Products Limited and Chugai Pharma UK Ltd, speaker honoraria from Roche Products Limited, Bayer and Novo Nordisk, meeting support from Novo Nordisk and Bayer. K Jenner. Unrestricted educational grant from Roche Products Limited and Chugai Pharma UK Ltd. L. Pembroke. Unrestricted educational grant from Roche Products Limited and Chugai Pharma UK Ltd, Consultancy fees from Roche Products Limited, Bayer, Biomarin and Sobi, Speaker Honoraria from Biomarin, Sobi, Novo Nordisk and Chugai. M Holland. Unrestricted educational grant from Roche Products Limited and Chugai Pharma UK Ltd. K Khair. Unrestricted educational grant from Roche Products Limited and Chugai Pharma UK Ltd, Consultancy fees from Bayer, Novo Nordisk, Sobi and Takeda, Speaker honoraria from Bayer, Biomarin, Novo Nordisk, Sobi, Pfizer and Takeda.
